Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesReevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity
Journal of Rheumatology, 10/20/09
Khan NA et al. – MS duration has a moderate correlation with RA disease activity. Assessment of MS duration may be clinically helpful in patients with low RAPID3 scores.
Methods- 5439 patients in QUEST-RA
- MS duration assessed from time of waking to time of maximal improvement
- Ability of MS duration to differentiate RA activity states, based on Disease Activity Score (DAS)28, assessed by analysis of variance; and receiver-operating characteristic (ROC) curve plotted for discriminating clinically active (DAS28 ≥ 3.2) from less active (DAS28 ≤ 3.2) RA
- Mixed-effect analysis of covariance (ANCOVA) models used to assess utility of adding MS duration to Routine Assessment of Patient Index Data (RAPID) 3, a PRO index based on physical function, pain, and general health (GH), in predicting 3-variable DAS28 (DAS28v3)
- MS duration had moderate correlation with pain, Health Assessment Questionnaire, and GH; and weak correlation with joint counts and ESR
- MS duration differed significantly among patients with different RA activity
- Area under ROC curve of 0.74 (95% CI 0.72–0.75) showed moderate ability of MS duration to differentiate clinically active from less active RA
- ANCOVA showed significant interactive effects between RAPID3 and the MS duration categories in predicting DAS28v3
- Effect of MS found to be clinically important in patients with low RAPID3 scores (< 6) in whom presence of MS may indicate clinically active disease (DAS28v3 > 3.2)
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis
Rheumatology International, 12/16/09
Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures
Osteoporosis International, 12/15/09
Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-&alpha blocker therapy
Rheumatology, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor